

Contents

List of Contributors	<i>XIX</i>
Preface	<i>XXIX</i>
A Personal Foreword	<i>XXXI</i>

Part I Transversal Issues Concerning Animal Models in Drug Discovery 1

1	The 3Ns of Preclinical Animal Models in Biomedical Research 3
	<i>José Miguel Vela, Rafael Maldonado, and Michel Hamon</i>
1.1	First N: The Need for Use of Animal Models 3
1.2	Second N: The Need for Better Animal Models 5
1.2.1	Unbiased Design 8
1.2.2	Comprehensive Reporting 8
1.2.3	Selection of the Animal Model Based on Its Validity Attributes 9
1.2.4	Appropriate Time and Dosing 11
1.2.5	Use of Biomarkers 12
1.2.6	Use of Various Animal Models 13
1.2.7	Quantitative, Multiple, and Cross-Predictive Measurements 14
1.2.8	Pharmacokinetic–Pharmacodynamic Integration 15
1.2.9	Predefinition and Adherence to the Desired Product Profile 16
1.2.10	Comparison with Gold Standard References 18
1.2.11	Reverse Translation/Backtranslation (Bedside-to-Bench Approach) 18
1.3	Third N: The Need for 3Rs Guiding Principles 19
	References 22
2	Alternative Models in Drug Discovery and Development Part I: <i>In Silico</i> and <i>In Vitro</i> Models 27
	<i>Luz Romero and José Miguel Vela</i>
2.1	Introduction 27
2.2	<i>In Silico</i> Models 34
2.2.1	Quantitative Structure–Activity Relationship 34
2.2.2	Biokinetic Modeling 37

2.2.3	Disease- and Patient-Specific <i>In Silico</i> Models	42
2.3	<i>In Vitro</i> Models	43
2.3.1	Primary Cells, Cell Lines, Immortalized Cell Lines, and Stem Cells	44
2.3.2	Advanced <i>In Vitro</i> Models for the Prediction of Drug Toxicity	46
2.3.3	<i>In Vitro</i> Tumor Models	47
	References	50
3	Alternative Models in Drug Discovery and Development Part II: <i>In Vivo</i> Nonmammalian and Exploratory/Experimental Human Models	59
	<i>Luz Romero and José Miguel Vela</i>	
3.1	Introduction	59
3.2	<i>In Vivo</i> Nonmammalian Models	59
3.2.1	Zebrafish	61
3.2.2	<i>D. melanogaster</i>	66
3.2.3	<i>C. elegans</i>	71
3.3	<i>In Vivo</i> Exploratory and Experimental Human Models	74
3.3.1	Phase 0 (Exploratory Human Models): Microdosing Studies	76
3.3.2	Phase IB/IIA (Proof-of-Concept) Studies: Experimental Human Models	81
	References	84
4	Ethical Issues and Regulations and Guidelines Concerning Animal Research	91
	<i>David Sabaté</i>	
4.1	Introduction	91
4.2	Current Use of Animals in Biomedical and Pharmaceutical Research	92
4.3	Ethical Concerns and Positions on Animal Research	93
4.4	General Principles for the Ethical Use of Animals in Research	95
4.4.1	The 3Rs Principles (Replacement, Reduction, and Refinement)	95
4.4.2	The Principle of Justification	96
4.4.3	The Principle of Responsibility	97
4.5	Regulatory Framework for Use of Animals in Research	98
4.5.1	European Union	98
4.5.2	The United States	100
4.5.3	Canada	100
4.5.4	Japan	100
4.5.5	Australia	101
4.5.6	India	101
4.5.7	China	101
4.5.8	Brazil	102
4.5.9	Countries without a Specific Legal Framework	102
	Acknowledgment	102
	References	102

5	Regulatory Issues: Safety and Toxicology Assessment	107
	<i>Antonio Guzmán</i>	
5.1	Introduction	107
5.1.1	Animal Testing	107
5.1.2	Regulatory Context	109
5.1.3	Clinical Context	109
5.2	Animal Species in Toxicology Studies	110
5.2.1	Rodents	111
5.2.2	Nonrodents	112
5.2.3	Nonconventional Animal Models	114
5.3	Toxicology Studies	114
5.3.1	General Principles	114
5.3.2	General and Repeated Dose Toxicity Studies	116
5.3.3	Safety Pharmacology	118
5.3.4	Genotoxicity	119
5.3.5	Development and Reproductive Toxicity Studies	122
5.3.6	Carcinogenicity Studies	124
5.4	Translation to Clinics: Limitations and Difficulties	126
	References	127
6	Generation and Use of Transgenic Mice in Drug Discovery	131
	<i>Guillaume Pavlovic, Véronique Brault, Tania Sorg, and Yann Hérault</i>	
6.1	Introduction	131
6.2	Improved Mouse Genetic Engineering	133
6.2.1	Recent Technical Developments	133
6.2.2	The Advent of New Mouse Mutant Resource: One Stop Shop	133
6.3	Functional Evaluation and Uses of Mouse Models	136
6.3.1	Standardization and Harmonization	136
6.3.2	Genetic Background and Environmental Influences	137
6.3.3	Challenges Ahead	137
6.3.4	Target Identification and Translation to Humans	138
6.3.5	Use of GEMMs in Pharmaceutical Industry and Risk Assessment	139
6.4	Translation to Clinics: Limitations and Difficulties	140
6.5	Perspectives	142
	Acknowledgments	143
	References	143
7	<i>In Vivo</i> Brain Imaging in Animal Models: A Focus on PET and MRI	149
	<i>Fabien Chauveau, Mathieu Verdurand, and Luc Zimmer</i>	
7.1	Introduction: Role of Animal in <i>In Vivo</i> Imaging	149
7.1.1	<i>In Vivo</i> Imaging as a Translational Approach for Basic Research	149
7.1.2	<i>In Vivo</i> Imaging in Animal Models in the Pharmaceutical Industry	150
7.1.3	<i>In Vivo</i> Imaging in Animal Models and the 3R Principles	150

7.2	The Choice of the Right Imaging Modality for Brain Imaging	151
7.3	Small Animal Magnetic Resonance Imaging	152
7.3.1	Principles	152
7.3.2	Magnetic Resonance Spectroscopy	152
7.3.3	Magnetic Resonance Imaging	153
7.4	Positron Emission Tomography	155
7.4.1	Basic Principles and Instrumentation	155
7.4.2	PET and Neuronal Metabolism	155
7.4.3	PET and Brain Receptors and Transporters	156
7.4.4	PET and Receptor Occupancy	158
7.4.5	PET and Neurotransmitter Release	159
7.5	Clinical Translation: Limitations and Difficulties	159
7.5.1	Anesthesia	160
7.5.2	Spatial Resolution and Sensitivity	160
7.5.3	The Mass Effect of Injected Tracers	161
7.5.4	Multimodal PET–MRI for Better Clinical Translation	162
	References	163

Part II Animal Models in Specific Disease Areas of Drug Discovery 167

8	Substance Abuse and Dependence	169
	<i>Elena Martín-García, Patricia Robledo, Javier Gutiérrez-Cuesta, and Rafael Maldonado</i>	
8.1	Introduction	169
8.2	Difficulties to Model Addiction in Animals	170
8.3	Tolerance, Sensitization, and Physical Withdrawal	172
8.3.1	Tolerance	172
8.3.2	Sensitization	173
8.3.3	Physical Manifestations of Withdrawal	174
8.3.4	Affective Manifestations of Withdrawal	175
8.4	Reward and Reinforcement	177
8.4.1	Drug Discrimination	177
8.4.2	Conditioned Place Preference	178
8.4.3	Intracranial Self-Stimulation	180
8.4.4	Self-Administration	182
8.5	Translation to Clinics: Limitations and Difficulties	184
	References	186
9	Mood and Anxiety Disorders	193
	<i>Guy Griebel and Sandra Beeské</i>	
9.1	Introduction	193
9.2	Animal Models of Anxiety Disorders	194
9.2.1	Preclinical Measures of Anxiety	194
9.2.2	Preclinical Anxiety Models and Endophenotypes	195
9.3	Animal Models of Mood Disorders	197

9.3.1	Major Depressive Disorder	197
9.3.1.1	Preclinical Measures of Depression	198
9.3.1.2	Endophenotype Models of Depression	199
9.3.2	Bipolar Disorder	199
9.4	Translation to Clinics: Limitations and Difficulties	200
	Acknowledgment	201
	References	202
10	Schizophrenia	207
	<i>Ronan Depoortère and Paul Moser</i>	
10.1	Introduction	207
10.2	Models Amenable to Use in Screening	209
10.2.1	Models Based on the Use of Pharmacological Agents	209
10.2.1.1	Dopaminergic Agonists	209
10.2.1.2	NMDA/Glutamate Receptor Antagonists	211
10.2.1.3	Other Pharmacological Agents Used to Induce Behavioural Changes	212
10.2.1.4	5-HT _{2A} Receptor Agonists	212
10.2.1.5	Cannabinoid Receptor Agonists	212
10.2.1.6	Muscarinic Receptor Antagonists	213
10.2.1.7	Glycine B Receptor Antagonists	213
10.2.2	Models Not Based on the Use of Pharmacological Agents	213
10.2.2.1	Conditioned Avoidance Response	213
10.2.2.2	Potentiation of PPI of the Startle Reflex	214
10.2.3	Models More Time Consuming and/or Difficult to Implement	214
10.2.3.1	Models Aimed at Reproducing More Complex Symptoms of Schizophrenia	214
10.2.3.2	Models Aimed at Reproducing the Chronic Nature of Schizophrenia	216
10.2.3.3	Models Based on Genetic Manipulations	218
10.2.4	Models for Side Effects	218
10.2.4.1	Models for Motor Side Effects	219
10.2.4.2	Hyperprolactinemia	220
10.2.4.3	Sedation and Motor Incoordination	220
10.2.4.4	Models for Cognitive Side Effects	220
10.2.4.5	Metabolic Disorders Models	221
10.2.4.6	Models for Cardiovascular Effects	221
10.3	Translation to the Clinic: Limitations and Difficulties	221
10.3.1	Use of “Standard Subjects”	221
10.3.2	From Here to . . . ?	222
	References	223
11	Migraine and Other Headaches	231
	<i>Inger Jansen-Olesen, Sarah Louise T. Christensen, and Jes Olesen</i>	
11.1	Introduction	231
11.2	Vascular Models	231

11.2.1	<i>In Vitro</i>	232
11.2.2	<i>In Vivo</i>	233
11.3	Neurogenic Inflammation	234
11.4	Nociceptive Activation of the Trigeminovascular System	234
11.4.1	Electrophysiological Recordings on Primary Dural Afferents in Trigeminal Ganglion	237
11.4.2	Electrophysiological Recordings in Trigeminal Nucleus Caudalis	239
11.4.3	Histological Markers after Nociceptive Stimulation of the Trigeminovascular System	239
11.5	Cortical Spreading Depression	240
11.6	Human Experimental Migraine Provoking Models	241
11.7	Animal Experimental Migraine Provoking Models	242
11.8	Transgenic Models	246
11.9	Behavioral Models	246
11.9.1	Allodynia or Hyperalgesia	247
11.9.2	Face Grooming	248
11.9.3	Photophobia	248
11.9.4	Various Behaviors	249
11.10	Translation to Clinics: Limitations and Difficulties	249
	References	250

12 Nociceptive, Visceral, and Cancer Pain 261

Christophe Mallet, Denis Ardid, and David Balayssac

12.1	Introduction	261
12.2	Acute Pain Tests	261
12.2.1	Introduction	261
12.2.2	Electrical Stimulus	263
12.2.3	Thermal Stimulus	264
12.2.4	Mechanical Stimulus	264
12.2.5	Chemical Stimulus	265
12.3	Visceral Pain Models	265
12.3.1	Introduction	265
12.3.2	Pain Achievement Test	266
12.3.3	Animal Models	267
12.3.4	Pathophysiology and Pharmacology	269
12.4	Cancer Pain Models	270
12.4.1	Introduction	270
12.4.2	Pain Assessment in Animal Models of Cancer Pain	270
12.4.3	Animal Models	271
12.4.4	Pathophysiology and Pharmacology	272
12.4.5	Conclusions	272
12.5	Translation to Clinics: Difficulties and Limitations	273
12.5.1	Acute Pain Tests	273
12.5.2	Visceral Pain Models	274

12.5.3	Cancer Pain Models	274
12.5.4	Conclusions	275
	References	275
13	Inflammatory, Musculoskeletal/Joint (OA and RA), and Postoperative Pain	283
	<i>Laurent Diop and Yassine Darbaky</i>	
13.1	Introduction: Evaluation of Pain in Animal Models	283
13.2	Inflammatory Pain	287
13.2.1	Formalin Test	287
13.2.2	Carrageenan-Induced Hyperalgesia	287
13.2.3	Complete Freund's Adjuvant-Induced Hyperalgesia	288
13.2.4	Capsaicin-Induced Hyperalgesia	288
13.3	Musculoskeletal/Joint Osteoarthritis (OA) and Rheumatoid Arthritis (RA) Pain	289
13.3.1	Osteoarthritis Pain Models	289
13.3.2	Rheumatoid Arthritis Pain Models	293
13.4	Postoperative Pain	297
13.4.1	Incisional Pain	298
13.4.2	Laparotomy	299
13.4.3	Ovariohysterectomy	299
13.4.4	Other Models of Postoperative Pain	299
13.5	Translation to Clinics: Limitations and Difficulties	300
	References	302
14	Neuropathic Pain	305
	<i>Said M'Dahoma, Sylvie Bourgoin, and Michel Hamon</i>	
14.1	Introduction	305
14.2	Main Types of Neuropathic Pain in Humans	306
14.2.1	Neuropathic Pain Caused by Peripheral Nerve Lesions	306
14.2.1.1	Diabetes-Induced Neuropathic Pain	306
14.2.1.2	Human Immunodeficiency Virus-Related Pain	306
14.2.1.3	Postherpetic Neuralgia	307
14.2.1.4	Neuropathic Pain Caused by Anticancer Drugs	307
14.2.2	Neuropathic Pain Caused by Central Lesions	307
14.2.2.1	Spinal Cord Injury	307
14.2.2.2	The Various Types of Pain in SCI Patients	308
14.3	Modelization of Chronic Pain in Rodents	309
14.3.1	Models of Peripheral Nerve Injury	309
14.3.1.1	Nerve Section	309
14.3.1.2	Nerve Ligation, Compression, and Other Lesion Procedures	310
14.3.1.3	Drug- and Virus-Induced Neuropathic Pain	314
14.3.2	Models of Spinal Cord Injury	318
14.3.2.1	Spinal Cord Contusion	318
14.3.2.2	Clip Compression Injury	319

14.3.2.3	Spinal Cord Transection	319
14.3.2.4	Spinal Cord Ischemia	319
14.3.3	Neuropathic-Like Pain Evoked by Chemicals Administered at the Spinal Level	320
14.3.3.1	Intrathecal Administration of ATP	320
14.3.3.2	Intrathecal Administration of BDNF	320
14.3.3.3	Excitotoxic Injury to the Spinal Cord	321
14.4	Translation to Clinics: Limitations and Difficulties	321
	References	324
15	Obesity and Metabolic Syndrome	333
	<i>Sunil K. Panchal, Maharshi Bhaswant, and Lindsay Brown</i>	
15.1	Introduction	333
15.2	Why Metabolic Syndrome?	333
15.3	Classical Animal Models of Obesity and Metabolic Syndrome	335
15.3.1	Genetic Models of Obesity and Diabetes	336
15.3.2	Artificially Induced Metabolic Syndrome in Animals	337
15.3.2.1	Monosodium Glutamate-Induced Obesity	338
15.3.2.2	Intrauterine Growth-Restricted Rats	338
15.4	Human Experimental Models	344
15.5	Translation to Clinics: Difficulties and Limitations	344
	References	344
16	Cognitive Disorders: Impairment, Aging, and Dementia	349
	<i>Nick P. van Goethem, Roy Lardenoije, Konstantinos Kompotis, Bart P.F. Rutten, Jos Prickaerts, and Harry W.M. Steinbusch</i>	
16.1	Introduction	349
16.2	Pharmacological Models	349
16.2.1	Inhibition of Energy/Glucose Metabolism	350
16.2.2	Cholinergic Interventions	350
16.2.3	Glutamatergic Antagonists	352
16.2.4	Serotonergic Intervention	353
16.3	Aging and Transgenic Models	353
16.3.1	Normal Aging	354
16.3.2	Alzheimer's Disease	355
16.3.3	Parkinson's Disease	358
16.3.4	Huntington's Disease	358
16.3.5	Frontotemporal Dementia	359
16.3.6	Down Syndrome	360
16.4	Translation to Clinics: Limitations and Difficulties	360
	References	362
17	Stroke and Traumatic Brain Injury	367
	<i>Dominique Lerouet, Valérie C. Besson, and Michel Plotkine</i>	
17.1	Introduction	367

17.2	Stroke Models	368
17.2.1	Global Stroke Models	368
17.2.2	Focal Stroke Models	369
17.2.2.1	Extravascular Models	369
17.2.2.2	Photothrombosis Model	370
17.2.2.3	Intraluminal Occlusion Model	370
17.2.2.4	Thromboembolic Models	370
17.3	Traumatic Brain Injury Models	371
17.3.1	TBI Models with Craniotomy	372
17.3.1.1	Weight-Drop Model	372
17.3.1.2	Lateral Fluid Percussion Model	372
17.3.1.3	Controlled Cortical Impact Model	372
17.3.2	TBI Models without Craniotomy	372
17.3.2.1	Weight-Drop Model	373
17.3.2.2	Impact/Acceleration Model	373
17.3.2.3	Acceleration/Deceleration Model	373
17.3.3	Blast Injury Models	373
17.3.4	Repetitive TBI Models	374
17.4	Outcome Assessment	375
17.5	Translation to Clinics: Limitations and Difficulties	377
17.5.1	The Actual Target: From the Neuron to the Neurogliovascular Unit	377
17.5.2	From Bench to Bedside to Bench: Recommendations for Improving the Translational Research	378
	References	379
18	Movement Disorders: Parkinson's Disease	387
	<i>Houman Homayoun and Christopher G. Goetz</i>	
18.1	Introduction	387
18.1.1	Parkinson's Disease	387
18.2	Drug- and Toxin-Based Models of PD	389
18.2.1	Reserpine	389
18.2.2	Haloperidol	390
18.2.3	6-OHDA	390
18.2.4	MPTP	393
18.2.5	Rotenone	396
18.2.6	Paraquat and Other Environmental Toxins	398
18.3	Genetic and Functional Models of PD	398
18.3.1	Rodent Genetic Models	399
18.3.1.1	Adult-Onset Rodent Gene-Based Models	401
18.3.2	Rodent Function-Based Models	403
18.3.3	Nonrodent Genetic Models of PD	404
18.4	Translation to Clinics: Limitations and Difficulties	405
	References	409

19	Epilepsy: Animal Models to Reproduce Human Etiopathology	415
	<i>Isabelle Guillemain, Christophe Heinrich, and Antoine Depaulis</i>	
19.1	Introduction	415
19.2	What Animal Species to Use to Model Epilepsy?	416
19.3	Which Type of Models Provide the Most Reliable Information on the Pathophysiology of Epilepsies?	417
19.4	Modeling Four Prototypic Forms of Epilepsy	418
19.4.1	Idiopathic Generalized Epilepsies with Convulsive Seizures	418
19.4.2	Idiopathic Generalized Epilepsies with Absence Seizures	419
19.4.3	Focal Epilepsies Associated with Cortical Dysplasia	420
19.4.4	Modeling Focal Epilepsies Associated with Hippocampal Sclerosis	422
19.5	Translation to Clinics: Limitations and Difficulties	423
	References	425
20	Lung Diseases	431
	<i>Laurent Boyer, Armand Mekontso-Dessap, Jorge Boczkowski, and Serge Adnot</i>	
20.1	Introduction	431
20.2	Animal Models of Lung Emphysema or Chronic Obstructive Pulmonary Disease	432
20.2.1	Cigarette Smoke-Induced COPD	432
20.2.2	COPD Induced by Tracheal Elastase Instillation	433
20.2.3	Genetically Modified Models of COPD	434
20.2.4	Conclusions	434
20.3	Animal Models of Pulmonary Hypertension	434
20.3.1	Relevance of Experimental Animal Models of PH to Human PH	435
20.3.2	The Monocrotaline Model of Pulmonary Hypertension	436
20.3.3	Fawn-Hooded Rats	437
20.3.4	Hypoxic PH	437
20.3.5	SU5416 Treatment Combined with Hypoxia in Mice	438
20.3.6	PH Related to COPD or Smoke Exposure	439
20.4	Animal Models of Fibrotic Lung Diseases	439
20.4.1	Bleomycin-Induced Pulmonary Fibrosis	439
20.4.2	Other Models	440
20.5	Animal Models of Acute Respiratory Distress Syndrome	440
20.6	Translation to Clinics: Limitations and Difficulties	445
	References	446
21	Heart Failure	449
	<i>Jin Bo Su and Alain Berdeaux</i>	
21.1	Introduction	449
21.2	Hypertension-Related Heart Failure	450
21.3	Pressure and Volume Overload-Induced Heart Failure	452
21.3.1	Pressure Overload-Induced Heart Failure	452
21.3.2	Volume Overload-Induced Heart Failure	454

21.3.3	Double Pressure and Volume Overload-Induced Heart Failure	454
21.4	Toxic Molecule-Induced Heart Failure	455
21.4.1	Adriamycin-Induced Heart Failure in Rats	455
21.4.2	Monocrotaline-Induced Right Ventricular Heart Failure	455
21.5	Heart Failure Models Related to Myocardial Ischemia and/or Myocardial Infarction	456
21.5.1	Myocardial Ischemia and/or Myocardial Infarction	456
21.5.2	Coronary Microembolization-Induced Heart Failure	457
21.6	Pacing-Induced Heart Failure	458
21.7	Gene Mutation-Induced Cardiomyopathies	460
21.7.1	Cardiomyopathic Hamsters	460
21.7.2	Golden Retriever Muscular Dystrophy Dogs	460
21.7.3	Genetic Modification-Induced Cardiomyopathies in Mice	461
21.8	Translation to Clinics: Limitations and Difficulties	462
	References	462

22 Endocrine Disorders 473

Thomas Cuny, Anne Barlier, and Alain Enjalbert

22.1	Introduction	473
22.2	Animal Models in Autoimmune Endocrine Diseases	474
22.2.1	Animal Models of Autoimmune Thyroiditis	474
22.2.2	Animal Models for Addison's Disease	476
22.2.3	Animal Models for Other Endocrine Autoimmune Diseases	476
22.3	Animal Models in Endocrine Tumors	477
22.3.1	Multiple Endocrine Neoplasia Syndromes	477
22.3.2	Adrenal Tumorigenesis	478
22.3.3	Thyroid Tumorigenesis	481
22.3.4	Pituitary Tumorigenesis	482
22.4	Animal Models in Endocrine Physiology: Organogenesis, Reproduction, and Metabolism	485
22.4.1	Pituitary Development Disorders: Lessons from Animal Models	485
22.4.2	Animal Models and Reproductive Function	487
22.4.3	Animal Models Used in Calcium Homeostasis Studies	489
22.5	Translation to Clinics: Limitations and Difficulties	490
	References	491

23 Gastrointestinal Disorders: A Patho-biotechnology Approach to Probiotic Therapy 497

Roy D. Sleator

23.1	Introduction	497
23.2	Delivery: Improving Probiotic Resistance to Process-Induced Stresses and Storage Conditions	498
23.3	Survival: Improving Probiotic–Host Colonization	500

23.4	Efficacy: “Designer Probiotics”	500
23.5	Translation to Clinics: Limitations and Difficulties	501
	Acknowledgment	502
	References	502
24	Renal Disorders	505
	<i>Dominique Guerrot, Christos Chatziantoniou, and Jean-Claude Dussaule</i>	
24.1	Introduction	505
24.2	Animal Models	506
24.2.1	The RenTg Model of CKD	507
24.2.1.1	Benefits of the RenTg Model	509
24.2.2	Unilateral Ureteral Obstruction	510
24.2.2.1	Technical Aspects	510
24.2.2.2	Pathology and Pathophysiology	511
24.2.2.3	Clinical Relevance and Limits	511
24.2.3	Renal Ischemia–Reperfusion	511
24.2.3.1	Technical Aspects	512
24.2.3.2	Pathology and Pathophysiology	512
24.2.3.3	Clinical Relevance and Limits	513
24.2.4	Experimental Alloimmune Glomerulonephritis	513
24.2.4.1	Technical Aspects	513
24.2.4.2	Pathology and Pathophysiology	514
24.2.4.3	Clinical Relevance and Limits	514
24.2.5	Angiotensin II-Mediated Hypertensive Nephropathy	514
24.2.5.1	Technical Aspects	515
24.2.5.2	Pathology and Pathophysiology	515
24.2.5.3	Clinical Relevance and Limits	516
24.2.6	l-NAME-Mediated Hypertensive Nephropathy	516
24.2.6.1	Technical Aspects	516
24.2.6.2	Pathology and Pathophysiology	516
24.2.6.3	Clinical Relevance and Limits	517
24.3	Translation to Clinics: Limitations and Difficulties	518
	References	518
25	Genitourinary Disorders: Lower Urinary Tract and Sexual Functions	523
	<i>Pierre Clément, Delphine Behr-Roussel, and François Giuliano</i>	
25.1	Introduction	523
25.2	Lower Urinary Tract Function	523
25.2.1	Physiology of Micturition	524
25.2.2	Investigation of Lower Urinary Tract Function	524
25.2.2.1	Cystometry Evaluation	524
25.2.2.2	Evaluation of Urethral Function	525
25.2.2.3	Bladder Afferent Recording	526
25.2.3	Pathophysiological Models	527

25.2.3.1	Bladder Outlet Obstruction	527
25.2.3.2	Overactive Bladder	527
25.2.3.3	Neurogenic Detrusor Overactivity	528
25.2.3.4	Painful Bladder Syndrome/Interstitial Cystitis	528
25.3	Sexual Functions	529
25.3.1	Physiology of Female and Male Sexual Response	529
25.3.2	Models for Sexual Behavior	530
25.3.2.1	Sexual Preference Paradigms	530
25.3.2.2	Copulatory Tests	531
25.3.3	Investigation of the Peripheral Female Sexual Response	532
25.3.4	Investigation of Erection	532
25.3.4.1	Penile Reflex	532
25.3.4.2	Erection in Conscious Animals	533
25.3.4.3	Intracavernosal Pressure Measurement	533
25.3.4.4	Pharmacologically Induced Erection	534
25.3.4.5	Neurally Evoked Erection	534
25.3.5	Investigation of Ejaculation	534
25.3.5.1	Physiological Markers of Emission and Expulsion Phases	534
25.3.5.2	Pharmacologically Induced Ejaculation	535
25.3.5.3	Lumbar Spinothalamic Neurons Electrical Stimulation	535
25.3.5.4	Expulsion Spinal Reflex	535
25.3.6	Pathophysiological Models	536
25.3.6.1	Female Sexual Dysfunctions	536
25.3.6.2	Erectile Dysfunction	536
25.3.6.3	Ejaculatory Disorders	538
25.4	Translation to Clinics: Difficulties and Limitations	538
	References	540

Index	543
--------------	------------

